再生元(REGN)联合Alnylam(ALNY)RNA疗法Livsayis获FDA批准

金吾财讯
Nov 19

金吾财讯 | 再生元(REGN)与Alnylam Pharmaceuticals(ALNY)共同研发的RNA疗法Livsayis(cemdisiran)已在美国获批,用于治疗成人重症肌无力患者。重症肌无力是一种慢性自身免疫性疾病。这款小干扰RNA疗法的适应症为抗乙酰胆碱受体抗体阳性的全身型重症肌无力(gMG),这是该疾病最常见的类型。今年早些时候,FDA对cemdesiran新药申请授予优先审评资格,目标审评日期定于11月。根据双方全球许可协议,再生元负责生产和商业化这款注射药物。该新药申请依托3期NIMBLE试验数据支持,cemdesiran作为单药疗法,在有症状成人gMG患者中达到主要终点。Livsayis是首个也是唯一获批治疗gMG的siRNA疗法,同时也是再生元首款该类疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10